Thomas Haimowitz

Background

About Thomas Haimowitz

I am a seasoned pharmaceutical scientist with deep expertise across the drug development lifecycle—from early-stage discovery to process chemistry, CMC strategy, and cGMP drug substance manufacturing. With 15+ years of experience advancing small molecule therapeutics across oncology, infectious disease, and virology, I bring both scientific rigor and collaborative leadership to multidisciplinary drug development programs. I’ve contributed to the discovery and development of first-in-class therapies including birinapant (a bivalent SMAC mimetic for cancer and HBV) and remitinostat (a topical HDAC inhibitor for CTCL), driving efforts from hit-to-lead through IND-enabling studies. At TetraLogic Pharmaceuticals, I played key roles in PR & D, tech transfer, and regulatory submissions, including authoring and reviewing Drug Substance Module 3 and Master Batch Records for multiple IND filings. At Venatorx Pharmaceuticals, I lead PR & D and early CMC activities for multiple preclinical and Phase I/II programs. For VNRX-9945, an HBV capsid assembly modulator, I collaborated with our CDMO partners to transition the medicinal chemistry route into a scalable cGMP process, enabling multi-kilogram manufacture for clinical trials. I authored the Drug Substance Module 3 for IND submission and oversaw key analytical and regulatory deliverables. Currently, I direct development of VNRX-14808, a highly potent oxaborinine-based PBP inhibitor targeting carbapenem-resistant Acinetobacter baumannii. I’ve led efforts to produce kilogram-scale quantities for toxicology studies and initiated IND-enabling activities including impurity profiling, reference standard development, stability studies, and polymorph/salt form characterization. I’m seeking new opportunities as an Associate Director or Director of CMC, Principal Scientist, or Drug Discovery Lead where I can apply my cross-functional experience to advance transformative therapies. I thrive in collaborative environments, enjoy managing partner relationships, and bring a strong track record of bridging discovery and development with a focus on scientific excellence and regulatory quality.